BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10021913)

  • 1. Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket.
    Reiter LA; Rizzi JP; Pandit J; Lasut MJ; McGahee SM; Parikh VD; Blake JF; Danley DE; Laird ER; Lopez-Anaya A; Lopresti-Morrow LL; Mansour MN; Martinelli GJ; Mitchell PG; Owens BS; Pauly TA; Reeves LM; Schulte GK; Yocum SA
    Bioorg Med Chem Lett; 1999 Jan; 9(2):127-32. PubMed ID: 10021913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3.
    Reiter LA; Mitchell PG; Martinelli GJ; Lopresti-Morrow LL; Yocum SA; Eskra JD
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2331-6. PubMed ID: 12824028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors.
    Lovejoy B; Welch AR; Carr S; Luong C; Broka C; Hendricks RT; Campbell JA; Walker KA; Martin R; Van Wart H; Browner MF
    Nat Struct Biol; 1999 Mar; 6(3):217-21. PubMed ID: 10074939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for the highly selective inhibition of MMP-13.
    Engel CK; Pirard B; Schimanski S; Kirsch R; Habermann J; Klingler O; Schlotte V; Weithmann KU; Wendt KU
    Chem Biol; 2005 Feb; 12(2):181-9. PubMed ID: 15734645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virtual High-Throughput Screening for Matrix Metalloproteinase Inhibitors.
    Choi JY; Fuerst R
    Methods Mol Biol; 2017; 1579():259-271. PubMed ID: 28299742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterocycle-based MMP inhibitors with P2' substituents.
    Pikul S; Dunham KM; Almstead NG; De B; Natchus MG; Taiwo YO; Williams LE; Hynd BA; Hsieh LC; Janusz MJ; Gu F; Mieling GE
    Bioorg Med Chem Lett; 2001 Apr; 11(8):1009-13. PubMed ID: 11327577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship.
    Matter H; Schudok M; Schwab W; Thorwart W; Barbier D; Billen G; Haase B; Neises B; Weithmann K; Wollmann T
    Bioorg Med Chem; 2002 Nov; 10(11):3529-44. PubMed ID: 12213468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling.
    Park HI; Jin Y; Hurst DR; Monroe CA; Lee S; Schwartz MA; Sang QX
    J Biol Chem; 2003 Dec; 278(51):51646-53. PubMed ID: 14532275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. X-ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysin.
    Dunten P; Kammlott U; Crowther R; Levin W; Foley LH; Wang P; Palermo R
    Protein Sci; 2001 May; 10(5):923-6. PubMed ID: 11316871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor.
    Moy FJ; Chanda PK; Chen JM; Cosmi S; Edris W; Levin JI; Powers R
    J Mol Biol; 2000 Sep; 302(3):671-89. PubMed ID: 10986126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and activity of selective MMP inhibitors with an aryl backbone.
    Barta TE; Becker DP; Bedell LJ; De Crescenzo GA; McDonald JJ; Munie GE; Rao S; Shieh HS; Stegeman R; Stevens AM; Villamil CI
    Bioorg Med Chem Lett; 2000 Dec; 10(24):2815-7. PubMed ID: 11133099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
    Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
    J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S1' loop canonical conformation.
    Devel L; Garcia S; Czarny B; Beau F; LaJeunesse E; Vera L; Georgiadis D; Stura E; Dive V
    J Biol Chem; 2010 Nov; 285(46):35900-9. PubMed ID: 20817735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solution structure of the catalytic domain of human collagenase-3 (MMP-13) complexed to a potent non-peptidic sulfonamide inhibitor: binding comparison with stromelysin-1 and collagenase-1.
    Zhang X; Gonnella NC; Koehn J; Pathak N; Ganu V; Melton R; Parker D; Hu SI; Nam KY
    J Mol Biol; 2000 Aug; 301(2):513-24. PubMed ID: 10926524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily.
    Fabre B; Filipiak K; Díaz N; Zapico JM; Suárez D; Ramos A; de Pascual-Teresa B
    Chembiochem; 2014 Feb; 15(3):399-412. PubMed ID: 24449516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
    Spicer TP; Jiang J; Taylor AB; Choi JY; Hart PJ; Roush WR; Fields GB; Hodder PS; Minond D
    J Med Chem; 2014 Nov; 57(22):9598-611. PubMed ID: 25330343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and identification of conformationally constrained selective MMP inhibitors.
    Freskos JN; McDonald JJ; Mischke BV; Mullins PB; Shieh HS; Stegeman RA; Stevens AM
    Bioorg Med Chem Lett; 1999 Jul; 9(13):1757-60. PubMed ID: 10406637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.
    Pirard B; Matter H
    J Med Chem; 2006 Jan; 49(1):51-69. PubMed ID: 16392792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
    Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
    J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design.
    Grams F; Reinemer P; Powers JC; Kleine T; Pieper M; Tschesche H; Huber R; Bode W
    Eur J Biochem; 1995 Mar; 228(3):830-41. PubMed ID: 7737183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.